The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) encompasses members from industry, biotechnology, diagnostic, and non-profit organizations that have until recently been managed by the Foundation for the National Institutes of Health (FNIH) and provided financial and scientific support to ADNI programs. In this article, we review some of the major activities undertaken by the PPSB, focusing on those supporting the most recently completed National Institute on Aging grant, ADNI3, and the impact it has had on streamlining biomarker discovery and validation in Alzheimer’s disease. We also provide a perspective on the gaps that may be filled with future PPSB activities as part of ADNI4 and beyond.

The Private Partners Scientific board (PPSB) continues to play a key role in enabling several Alzheimer’s Disease Neuroimaging Initiative (ADNI) activities.
PPSB working groups have led landscape assessments to provide valuable feedback on new technologies, platforms, and methods that may be taken up by ADNI in current or future iterations.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Bruce Albala,
Eline Appelmans,
Ramona Burress,
Susan De Santi,
Theresa Devins,
Gregory Klein,
Veronika Logovinsky,
Gerald P. Novak,
Kim Ribeiro,
Mark E. Schmidt,
Adam J. Schwarz,
David Scott,
Sergey Shcherbinin,
Eric Siemers,
Alessio Travaglia,
Christopher J. Weber,
Leah White,
Julie Wolf‐Rodda,
Aparna Vasanthakumar | September 30, 2023

Wiley: Alzheimer’s & Dementia: Table of Contents